The Food and Drug Administration just announced its first public hearing pertaining to the implications of the recent legalization of CBD in food and beverages. With the recent explosion of CBD infusions in hundreds of commercially sold consumable products, many consumers feel as though this hearing could not have come soon enough.
The FDA is in search of scientific data on the safety and potential impact of CBD infused consumable products which might help to develop regulations for manufacturing, labeling, and marketing. This was made public in the Federal Register this week. The hearing is scheduled for May 31st at its headquarters located outside Washington, D.C.
Scott Gottlieb, the outgoing FDA Commissioner commissioned Lowell Schiller (Principal Associate Commissioner for Policy) and Amy Abernethy (Principal Deputy Commissioner) to co-chair a high-level group that would evaluate the issue.
In the statement on Tuesday, Gottlieb said, “It’s critical that we address these unanswered questions about CBD and other cannabis and cannabis-derived products to help inform the FDA’s regulatory oversight of these products—especially as the agency considers whether it could be appropriate to exercise its authority to allow the use of CBD in dietary supplements and other foods.”
Recently, the Federal Trade Commission and the FDA served three companies—PotNetwork Holdings, Nutra Pure, and Advanced Spine and Pain Relievus—warning letters for promoting their CBD products as a potential cure for Alzheimer’s disease and cancer as these claims are unsubstantiated and potentially severely misleading.
CBD is an abbreviation for cannabidiol, one of the hundreds of cannabinoids found within the cannabis plant. CBD is promoted as having the ability to relax the body without affecting the mind like THC.
Curious to know more about the latest news and find the best cannabis companies to invest in? Sign up for Cannin Free Access. Subscribe to Cannin Chronicles and stay informed on all things cannabis and help you determine which cannabis companies have the highest growth potential.